UNICYCIVE THERAPEUTICS INC
UNCY · NASDAQ
Updated at 2026-10-13 15:06:24
- Today's High
- $4.02
- Today’s Low
- $3.84
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $4.10
- Previous Close
- $4.05
- Volume
- 912.9K
- Market Cap
- $112.81M
- P/E Ratio
- --
- EPS
- $-1.61
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 1975 WEST EL CAMINO REAL, MOUNTAIN VIEW, CA, UNITED STATES, 94040
- Country
- US
- Listing Date
- 2021-06-17
- Fiscal Year End
- December
- Shares Outstanding
- 26.7M
- CIK
- 0001766140
- Website
- unicycive.com
Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on pioneering therapies for kidney diseases, particularly in the management of hyperphosphatemia. With its proprietary drug candidates aimed at effectively regulating phosphorus levels crucial for renal health, Unicycive is strategically positioned to address significant unmet medical needs within nephrology. The company's strong commitment to research and development, combined with its collaborative partnerships, enhances its potential for innovation and growth. As Unicycive advances through clinical trials, it represents a compelling investment opportunity for institutional investors targeting transformative solutions in the healthcare sector.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
Operating Expenses
2026-06-30
$10.14M
2026-03-31
$8.22M
2025-12-31
$7.22M
2025-09-30
$7.34M
Net Income
2026-06-30
-$1.72M
2026-03-31
-$12.82M
2025-12-31
-$14.66M
2025-09-30
-$6.01M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
Earnings Per Share
2026-06-30
$-0.06
2026-03-31
$-0.53
2025-12-31
$-0.82
2025-09-30
$-0.33
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$1.57M
2026-03-31
-$12.61M
2025-12-31
-$14.49M
2025-09-30
-$5.84M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | $10.14M | $8.22M | $7.22M | $7.34M |
| Net Income | -$1.72M | -$12.82M | -$14.66M | -$6.01M |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $-0.06 | $-0.53 | $-0.82 | $-0.33 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$1.57M | -$12.61M | -$14.49M | -$5.84M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.